Spero Therapeutics, Inc. (SPRO) Free cash flow 2016–2020
Spero Therapeutics, Inc. (SPRO) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$86.0MFY2020 · since FY2016: -$29.8M → -$86.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2020 | -$86.0M | -70.9% |
| FY2019 | -$50.3M | -19.7% |
| FY2018 | -$42.1M | -7.5% |
| FY2017 | -$39.1M | -31.4% |
| FY2016 | -$29.8M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice